Floatz logo

gb221

Spinal Muscular Atrophy, Type 1

Gemma Biotherapeuticsmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Spinal Muscular Atrophy, Type 1 cohort.

Asset / SponsorPhaseRating
Non-Replicating Recombinant Self-Complementary (Sc) Adeno-Associated Virus Serotype 9 (Aav9) Vector Containing The Cdna Of The Survival Of Motor Neuron 2 (Smn2) Gene Under The Control Of The Hybrid Cytomegalovirus (Cmv) Enhancer/Chicken Beta-Actin Promoter (Cba)
Novartis Gene Therapies
Phase 3BB
exg001-307
Guangzhou Jiayin Biotech Ltd
Phase 1/2CCC
Valproic Acid
University of Utah
Phase 1/2CCC
Levocarnitine
University of Utah
Phase 1/2CCC
Adipose Derived Mesenchymal Stem Cell
Tehran University of Medical Sciences
Phase 1/2CCC
Sodium Phenylbutyrate
Westat
Phase 1/2CCC
skg0201
Lanyue Biotech (Hangzhou) Co., Ltd.
Phase 1/2CCC

Same molecule, other indications

gb221 is also rated in:

HER2 positive breast carcinomaDormant
BB
Indicative · Phase 3
66 / 100
View asset →
breast cancerDormant
C
Indicative · Phase 1
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →